Clinical Trials

54 enrolled

Sarcoma

Liposarcoma, Liposarcoma, Myxoid

NCT02896335 2026-03-12

Palbociclib and Pembrolizumab In Central Nervous System Metastases

CNS

Brain Neoplasms

NCT05627232 2026-03-12

Tazemetostat and Palbociclib With CPX-351for R/R AML

Other hematologic neoplasm

24 enrolled

Leukemia, Myeloid, Acute

NCT03446157 2026-03-10

Palbociclib and Cetuximab in Metastatic Colorectal Cancer

24 enrolled 14 charts

Phase 2 Not yet recruiting

Colonic Neoplasms

NCT07123090 2026-02-27

SPARCC

25 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02778685 2026-02-24

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

47 enrolled 17 charts

Breast Neoplasms

NCT02693535 2026-02-13

TAPUR

GastrointestinalGynecologicHead & Neck

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT03065062 2026-02-13

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Phase 1 Suspended

75 enrolled

Head and Neck Neoplasms, Neoplasms, Pancreatic Neoplasms, Endometrial Neoplasms

NCT02624973 2026-02-12

PETREMAC

200 enrolled

Breast Neoplasms

NCT03170206 2026-02-12

Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Phase 1 Completed

34 enrolled

Thoracic

Lung Neoplasms

NCT04360941 2026-01-21

PAveMenT

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02668666 2026-01-20

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

49 enrolled 14 charts

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT03065387 2026-01-12

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

93 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07299890 2025-12-23

An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer

Phase 2 Not yet recruiting

90 enrolled

Breast Neoplasms

NCT05069038 2025-12-22

Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy

51 enrolled

Breast Neoplasms

NCT04563507 2025-12-15

Combined Immunotherapies in Metastatic ER+ Breast Cancer

102 enrolled

Breast Neoplasms

NCT02738866 2025-12-10

Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor

60 enrolled

Breast Neoplasms

NCT01723774 2025-12-09

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

84 enrolled 17 charts

Breast Neoplasms

NCT06753747 2025-12-03

A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma

Esophageal Neoplasms

NCT03079011 2025-11-18

PADA-1

Phase 3 Completed

1,017 enrolled

Breast Neoplasms

NCT06062498 2025-10-20

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

174 enrolled

Breast Neoplasms

NCT04438824 2025-10-14

Palbociclib and INCMGA00012 in People With Advanced Liposarcoma

42 enrolled

Sarcoma

Liposarcoma

NCT03147287 2025-09-30

Palbociclib After CDK and Endocrine Therapy (PACE)

220 enrolled 11 charts

Phase 1 Active not recruiting

Breast Neoplasms

NCT03959891 2025-09-29

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

77 enrolled

Breast Neoplasms

NCT03535506 2025-09-26

WI223281

Phase 2 Terminated

17 enrolled 9 charts

Phase 2 Not yet recruiting

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT07191977 2025-09-25

Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma

41 enrolled

Esophageal Squamour Cell Cancer

NCT03454035 2025-09-11

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

DermatologicGastrointestinal

Melanoma, Neoplasms, Pancreatic Neoplasms

NCT01907607 2025-08-24

CYCLIGIST

29 enrolled 8 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT02730429 2025-07-31

Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer

78 enrolled

Gynecologic

Endometrial Neoplasms

NCT01356628 2025-07-28

A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer

23 enrolled 12 charts

Phase 1/2 Active not recruiting

Liver Neoplasms

NCT03304080 2025-07-18

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

44 enrolled

Phase 1/2 Active not recruiting

Breast Diseases, Breast Neoplasms

NCT02605486 2025-07-03

Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)

46 enrolled

Breast Neoplasms

NCT06947811 2025-06-04

APEAK

71 enrolled

EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor

NCT06113809 2025-06-03

Palbociclib and Pembrolizumab in Sarcoma

Other hematologic neoplasm

8 enrolled

Sarcoma

NCT03844997 2025-05-31

Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia

Phase 1/2 Completed

35 enrolled 15 charts

Leukemia, Myeloid, Acute

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

423 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT03472573 2025-05-15

Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Phase 1 Completed

7 enrolled

Lymphoid

Burkitt Lymphoma

NCT02764541 2025-05-07

Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

195 enrolled 26 charts

Breast Neoplasms, Carcinoma, Lobular

NCT02040857 2025-04-29

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

162 enrolled 12 charts

Phase 3 Active not recruiting

Breast Neoplasms

NCT05207709 2025-04-29

HARMONIA

456 enrolled

Phase EARLY_PHASE1 Recruiting

Breast Neoplasms

NCT05432518 2025-04-25

Pilot Trial for Treatment of Recurrent Glioblastoma

10 enrolled

CNS

Glioblastoma, Recurrence

NCT06940349 2025-04-23

COPS-01

100 enrolled

Other solid neoplasm

Solid Tumors Refractory to Standard Therapy

NCT03389477 2025-04-13

Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma

Phase 1 Active not recruiting

26 enrolled 12 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03498378 2025-04-03

Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

24 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT06895733 2025-03-26

Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)

Phase NA Not yet recruiting

65 enrolled

Other solid neoplasm

Solid Tumor, Adult

NCT06810492 2025-03-17

The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment

40 enrolled

Breast Neoplasms

NCT04841148 2025-03-11

PALAVY

96 enrolled

Breast Neoplasms, Neoplasm, Residual

NCT06856200 2025-03-04

A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

Phase NA Recruiting

36 enrolled